Analysts divided on Clovis stock after drug approval is delayed
April 13, 2016 at 11:48 AM EDT
Clovis’ lung cancer drug may now take years for an approval decision, leaving analysts at odds about what the news means for the company.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.